Isthmus Partners LLC Sells 7,005 Shares of Ingevity Corporation $NGVT

Isthmus Partners LLC lowered its position in shares of Ingevity Corporation (NYSE:NGVT) by 9.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 65,240 shares of the company’s stock after selling 7,005 shares during the quarter. Isthmus Partners LLC owned about 0.18% of Ingevity worth $4,647,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Millennium Management LLC lifted its position in Ingevity by 1.3% during the 3rd quarter. Millennium Management LLC now owns 1,189,524 shares of the company’s stock valued at $65,650,000 after acquiring an additional 15,562 shares during the period. Royce & Associates LP grew its holdings in Ingevity by 7.7% in the fourth quarter. Royce & Associates LP now owns 1,111,158 shares of the company’s stock worth $65,758,000 after purchasing an additional 79,059 shares during the period. Brown Advisory Inc. increased its stake in shares of Ingevity by 15.4% during the fourth quarter. Brown Advisory Inc. now owns 1,040,944 shares of the company’s stock valued at $61,603,000 after purchasing an additional 138,859 shares in the last quarter. Simcoe Capital Management LLC increased its stake in shares of Ingevity by 9.4% during the fourth quarter. Simcoe Capital Management LLC now owns 1,020,945 shares of the company’s stock valued at $60,420,000 after purchasing an additional 87,490 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Ingevity by 7.4% during the fourth quarter. Victory Capital Management Inc. now owns 867,915 shares of the company’s stock valued at $51,363,000 after purchasing an additional 60,163 shares in the last quarter. Institutional investors own 91.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Ingevity in a research report on Tuesday, April 21st. Wall Street Zen raised Ingevity from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Ingevity currently has an average rating of “Hold” and an average price target of $80.00.

Insider Buying and Selling at Ingevity

In related news, SVP Terrance M. Dyer sold 496 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $68.49, for a total value of $33,971.04. Following the completion of the transaction, the senior vice president directly owned 7,202 shares in the company, valued at $493,264.98. The trade was a 6.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.88% of the stock is owned by company insiders.

Ingevity Price Performance

NGVT opened at $71.45 on Thursday. The firm has a market cap of $2.48 billion, a PE ratio of -20.13 and a beta of 1.16. The stock has a 50-day moving average price of $71.05 and a 200-day moving average price of $69.49. Ingevity Corporation has a 1 year low of $39.74 and a 1 year high of $79.29. The company has a debt-to-equity ratio of 27.83, a current ratio of 1.42 and a quick ratio of 0.92.

Ingevity (NYSE:NGVT) last released its quarterly earnings data on Wednesday, May 6th. The company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.31. The business had revenue of $258.00 million during the quarter, compared to analyst estimates of $254.73 million. Ingevity had a negative net margin of 10.55% and a positive return on equity of 207.82%. Ingevity’s revenue was up 4.1% compared to the same quarter last year. During the same period last year, the business earned $1.01 EPS. Ingevity has set its FY 2026 guidance at 4.700-5.200 EPS. Sell-side analysts predict that Ingevity Corporation will post 5.05 earnings per share for the current fiscal year.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.